Clinical Trial Listings

Formal Study Name:  Engendering Reproductive Health Within Oncologic Survivorship
Anatomic Site:
Any
Histology:
Pre-Menopausal Women (18-55) with Cancer
Mutation:
Stage:
Treatment Phase:  
Formal Study Name:  A Pragmatic trial to Improve Colony Stimulating Factor for Use in Cancer
Anatomic Site:
Breast, GI, Lung
Histology:
Metastatic, Non-metastatic, Non-Small Cell Lung Cancer (NSCLC), Non-Small Cell Lung Carcinoma
Mutation:
Stage:
Breast: Stage 0, Stage IA, Stage IB, Stage IIA, Stage IIB, Stage IIIA, Stage IIIB, Stage IIIC, Stage IV; Colorectal: Stage 0, Stage I, Stage IIA, Stage IIB, Stage IIC, Stage IIIA, Stage IIIB, Stage IIIC, Stage IVA, Stage IVB; NSCLC: Stage 0, Stage IIA, Stage IIB, Stage IV; Carcinoma: Stage IA, Stage IB, Stage IIA, Stage IIB
Treatment Phase:  Patient has current diagnosis. Patient has not had systemic therapy for their diagnosis (or not had systemic therapy for different diagnosis within 180 days)
Locations Where Open:
Formal Study Name:  Molecular Analysis for Therapy Choice (MATCH)
Anatomic Site:
Any
Histology:
Advanced Malignant Neoplasm, Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Solid Neoplasm, Refractory Malignant Neoplasm, Refractory Plasma Cell Myeloma
Mutation:
EGFR, HER2, EGFR T790M, BRAF V600E/R/K/D, PIK3CA, PTEN, PTEN deletion, PTEN loss, HER2 amplification, BRAF fusion, BRAF non-V600, NF 1, GNAQ, GNA11, SMO, PTCH1, NF2 inactivating, cKIT exon 9, cKIT exon 11, cKIT exon 13, cKIT exon 14, FGFR pathway aberrations, DDR2 S768R, I638F, L239R, Akt, NRAS in codon 12, NRAS in codon 13, NRAS in codon 61, CCND1, 2, or 3 amplification with Rb by IHC, Loss of MLH1 or MSH2 by IHC.
Stage:
Advanced
Treatment Phase:  Patient must have histologically documented solid tumors or confirmed diagnosis of lymphoma or multiple myeloma requiring therapy. Patients must have progressed following at least one line of standard systemic therapy; no standard treatment exists for their disease. Must have measurable disease
Formal Study Name:  Communication and Education in Tumor Profiling: A Randomized Study of Pre-disclosure Genetic Education v. Usual Care in Tumor Profiling for Adv. Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling
Anatomic Site:
Any
Histology:
Advanced Malignant Neoplasm, Locally Advanced Malignant Neoplasm
Mutation:
Potential Germline mutations
Stage:
Advanced
Treatment Phase:  Patients must have a potential germline mutation – as determined by MATCH trial (EAY131)
Formal Study Name:  The National Myelodysplastic Syndromes (MDS) Study
Anatomic Site:
Blood and Marrow
Histology:
Myelodysplastic Syndromes (MDS)
Mutation:
Stage:
Any
Treatment Phase:  Patients suspected to have MDS and are undergoing diagnostic work-up with planned bone marrow assessments to confirm MDS or to evaluate disease status.
Locations Where Open:
Formal Study Name:  A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Anatomic Site:
Breast
Histology:
Breast Cancer with Positive Sentinel Lymph Node(s)
Mutation:
Stage:
Stage II, Stage IIIA
Treatment Phase:  No previous neoadjuvant endocrine or radiation therapy. No SLN surgery.
Formal Study Name:  Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Anatomic Site:
Breast
Histology:
Invasive Breast Carcinoma
Mutation:
Her-2 negative
Stage:
ER and PR negative: T2 or T3 N0, or T0-3 N1-3; ER and/or PR positive: T0-3 N1-3, or T3 N0
Treatment Phase:  Patients must have histologically confirmed invasive breast cancer. All adjuvant or neoadjuvant chemotherapy, radiation, and surgery must be completed; must have sentinel lymph node biopsy and/or axillary lymph node dissection.
Formal Study Name:  A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Anatomic Site:
Breast
Histology:
Breast Carcinoma, Breast Cancer
Mutation:
Any Estrogen/Progesterone status, HER-2 negative
Stage:
Node-positive, anatomic stage II or III
Treatment Phase:  Patients must be within one year of diagnosis and free of recurrence. Histologic documentation of node positivity is required. Chemotherapy or radiation therapy must be completed. Concurrent hormonal therapy is allowed.
Formal Study Name:  Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Anatomic Site:
Breast
Histology:
Breast Carcinoma, Breast Cancer
Mutation:
HER2-negative, ER-positive
Stage:
Carcinoma: Invasive Ductal, Invasive Lobular; Cancer: Stage II, Stage IIIA, Stage IIIB, Stage IIIC
Treatment Phase:  Postmenopausal women with pathologic confirmation of invasive breast cancer diagnosed by core needle biopsy.
Formal Study Name:  A Randomized Ph. III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor+ Advanced Breast Cancer
Anatomic Site:
Breast
Histology:
Breast Carcinoma, Breast Cancer
Mutation:
HER2/NEU Negative; Estrogen Receptor Positive; Progesterone Receptor Positive
Stage:
Carcinoma: Male, Recurrent; Cancer: Stage IIIB, Stage IIIC, Stage IV
Treatment Phase:  ER and/or PR positive histologically confirmed adenocarcinoma at any time during treatment prior to study. May have received only one prior chemotherapy regiment.
Formal Study Name:  A Randomized Phase III Post-Operative Trial of Platinum Based Chemo vs. Observation in Patients with Residual Triple- Basal-Like Breast Ca post Neoadj. Chemo
Anatomic Site:
Breast
Histology:
Invasive Breast Carcinoma, Breast Cancer
Mutation:
Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Triple Negative
Stage:
Stage IIA, Stage IIB, Stage IIIA, Stage IIIB, Stage IIIC
Treatment Phase:  Must have histologically confirmed triple negative invasive breast cancer, clinical stage II-III at diagnosis. Patients must have completed neoadjuvant regimen and completed definitive resection of primary tumor.
Formal Study Name:  A Randomized Ph.3 Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Anatomic Site:
Breast
Histology:
Breast Cancer
Mutation:
Stage:
Stage II, Stage III
Treatment Phase:  Patient must have clinically T1-3, NI breast cancer at time of diagnosis (before neoadjuvant therapy), estrogen receptor analysis performed before neoadjuvant chemotherapy, and must have completed a minimum of 12 weeks of standard neoadjuvant chemotherapy.
Formal Study Name:  Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
Anatomic Site:
Breast
Histology:
Breast Carcinoma
Mutation:
Estrogen Negative, Progesterone Negative, HER2/NEU Negative, and/or BRCA1 or BRCA2 Mutation
Stage:
Stage IV
Treatment Phase:  Patients must have measurable or non-measurable disease. Must have had =< 1 prior cytotoxic regimen for metastatic disease and completed any prior radiation therapy or hormonal therapy.
Formal Study Name:  A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors With Cognitive Impairment
Anatomic Site:
Breast
Histology:
Invasive Breast Cancer
Mutation:
Stage:
History of breast cancer
Treatment Phase:  Must have completed at least 4 cycles of adjuvant/neo-adjuvant cytoxic chemotherapy. No evidence of suspected recurrent or metastatic disease. Self-reported cognitive complaint and documented measured memory deficit.
Formal Study Name:  A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Anatomic Site:
GI
Histology:
Colon Cancer, Rectal Cancer
Mutation:
Stage:
Stage 0, I, II, or III
Treatment Phase:  Patients must have received primary resection 1 year previously and be at least 30 days from completion of adjuvant chemotherapy and radiation therapy.
Formal Study Name:  Implementation of a Prospective Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer
Anatomic Site:
GI
Histology:
Colon Cancer, Rectal Cancer
Mutation:
Stage:
Colon Cancer: Stage IVA, Stage IVB; Rectal Cancer: Stage IVA, Stage IVB
Treatment Phase:  Patients must have newly diagnosed metastatic colon or rectal cancer (de novo metastatic diagnosis or metastatic recurrence) after prior treatment for stage I-III disease
Formal Study Name:  A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Anatomic Site:
GI
Histology:
Pancreatic Adenocarcinoma
Mutation:
Stage:
Must have resectable primary tumor based on contrast-enhanced CT or MRI
Treatment Phase:  Patients must have histologically or cytologically proven pancreatic adenocarcinoma and measurable disease in the pancreas. Must not have received prior surgery, radiation therapy, chemotherapy, targeted therapy, or any investigational therapy for pancreatic cancer.
Formal Study Name:  Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Anatomic Site:
Lung
Histology:
Non-Small Cell Lung Cancer (NSCLC), Non-Small Cell Lung Carcinoma
Mutation:
EGFR exon 19 deletion; L858R mutation
Stage:
NSCLC: Stage IB, Stage IIA, Stage IIB; Carcinoma: Stage IIA
Treatment Phase:  Previously registered to A151216 with an EGFR exon 19 deletion or L858R mutation, have complete recovery from surgery and standard post-operative therapy.
Formal Study Name:  Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST screening trial)
Anatomic Site:
Lung
Histology:
Squamous, Non-Small Cell Lung Cancer (NSCLC), Large Cell Lung Carcinoma
Mutation:
Stage:
Squamous & SCLC: Stage IB, Stage IIA, Stage IIB, Stage IIIA
Treatment Phase:  Patients with suspected diagnosis of resectable or completely resected NSCLC and have not received neoadjuvant therapy for this cancer.
Formal Study Name:  Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide
Anatomic Site:
Lung
Histology:
Small-Cell Lung Cancer (SCLC)
Mutation:
None
Stage:
Limited Stage
Treatment Phase:  Histologically or cytologically documented SCLC restricted to one hemiothorax. Patient may have received one and only one cycle of chemotherapy.
Formal Study Name:  A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Anatomic Site:
Lung
Histology:
Non-Small Cell Lung Carcinoma, Non-Small Cell Lung Cancer (NSCLC)
Mutation:
Fusion
Stage:
Carcinoma: Stage IB, Stage IIA, Stage IIB; NSCLC: Stage IIIA
Treatment Phase:  Patients have undergone complete surgical resection of their cancer and have negative margins and registered to A151216.
Formal Study Name:  A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer
Anatomic Site:
Lung
Histology:
Squamous
Mutation:
None
Stage:
Stage IV
Treatment Phase:  Must have completed at least one round of treatment
Formal Study Name:  A Ph.3 Randomized Study of Nivolumab + Ipilimumab vs. Nivolumab for Previously Treated Patients with St.IV Squamous Cell Lung Cancer and No Matching Biomarker
Anatomic Site:
Lung
Histology:
Squamous
Mutation:
None
Stage:
Stage IV
Treatment Phase:  Must have completed at least one round of treatment
Formal Study Name:  Improving Resection Rates among African Americans with Non-Small Cell Lung Cancer (“Southern Lung Cancer Study”)
Anatomic Site:
Lung
Histology:
Non-Small Cell Lung Cancer
Mutation:
Stage:
Stage I, Stage II
Treatment Phase:  Recently diagnosed with clinically suspicious or biopsy-proven non-small cell lung cancer. Must not have undergone surgical resection or radiotherapy for recently diagnosed lung cancer.
Formal Study Name:  A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Anatomic Site:
Lung
Histology:
Squamous Cell Carcinoma
Mutation:
Mutation in any one of the following critical HRR pathway genes: ATM, ATR, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCF, FANCM, NBN (NBS1), PALB2, RAD51, RAD51B (RAD51L1), RAD54L, RPA1
Stage:
Stage IV
Treatment Phase:  Patients must have achieved stable disease, a partial response, or a complete response at their first disease assessment after initiating firstline platinum-based chemotherapy.
Formal Study Name:  A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naïve Patients with Advanced, EGFR+ Non-Small Cell Lung Cancer
Anatomic Site:
Lung
Histology:
Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
Mutation:
EGFR exon 19 deletion; EFGR econ 21 (L858R) substitution; T790M mutation
Stage:
NSCLC: Stage IV Carcinoma: Recurring
Treatment Phase:  Patients have histologically or cytologically confirmed stage IV or recurrent NSCLC and documented presence of mutation. Patients must not have received any prior systemic anticancer therapy.
*TEMPORARILY CLOSED*
Formal Study Name:  A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Anatomic Site:
Lung
Histology:
Non-Small Cell Carcinoma
Mutation:
KRAS Gene Mutation
Stage:
Stage IV, Recurrent
Treatment Phase:  Patients must have pathologically confirmed KRAS mutation positive non-small cell lung cancer (NSCLC) that is stage IV or recurrent. Patients must have documented progressive cancer following at least one but no more than two prior regimens of systemic therapy for lung cancer, one of which must have been platinum based combination chemotherapy.